{
  "status_code": 200,
  "request": {
    "project_description": "Comprehensive genomic profiling/NGS in solid cancers.",
    "research_questions": [
      "What is the incidence and prevalence of advanced cancers in Europe and other key jurisdictions?\n-   Focus on France, Italy, Spain, Belgium, Switzerland, UK; also include data for rest of Europe and Brazil, Chile, Columbia, Mexico, Canada.",
      "What are EMA-approved and ESMO guideline-recommended biomarker-guided treatments in advanced cancer types?\n-   Focus on the use of genomic testing in non-small-cell lung cancer, colorectal cancer, malignant melanoma, ovarian cancer and breast cancer, to reflect the different number and type of biomarkers associated with each type of malignant disease",
      "What are the types of precision medicine approaches in advanced cancers in Europe (that is, finding treatments that are effective for specific genomic biomarkers in a solid tumor)?\n-   Targeted therapies for specific cancer types\n-   Tissue-agnostic (pan-cancer) therapies\n-   Multi-tumor type targeted therapies\n-   Biomarker-based immunotherapy approaches\n-   Emerging molecularly targeted therapies and ongoing clinical trials",
      "What are the unmet needs with current practice of genomic testing in advanced cancers in Europe?\n-   What are the existing technologies for genomic testing?\n-   What are the technology requirements for identification of specific types of genomic aberrations?\n-   What are the key unmet needs in genomic testing workup approaches in current clinical practice?\n-   What are the challenges faced by people trying to implement genomic testing for rate mutations?",
      "What is the clinical utility of comprehensive genome profiling (CGP)?\n-   How far does CGP offer broader coverage of medically necessary biomarkers than more traditional methods of identifying mutations, such as polymerase chain reaction (PCR), chromosomal microarray (CMA) \u00c2\u00a0or small gene panel assays?\n-   Is the accuracy of CGP higher than traditional approaches in detecting biomarkers?\n-   Does the use of CGP improve patient outcomes, for example, do patients respond better to, or live longer with, therapies that target the patient's specific mutation?\n-   Does the use of CGP mean that fewer biopsy samples are needed?\n-   Does the use of CGP increase the number of patients who are eligible to be enrolled in clinical trials of new targeted therapies?",
      "Economic impact\n-   What is the budget impact of adopting CGP compared with traditional genetic testing?\n-   What is the cost-effectiveness of CGP?"
    ],
    "mock": false
  },
  "response": {
    "elements": {
      "population": {
        "explicit": [
          "Patients with advanced solid cancers",
          "Patients in Europe and specified countries (France, Italy, Spain, Belgium, Switzerland, UK, rest of Europe, Brazil, Chile, Columbia, Mexico, Canada)"
        ],
        "implicit": [
          "Adults (pediatric cancers not mentioned)",
          "Patients with specific cancer types: non-small-cell lung cancer, colorectal cancer, malignant melanoma, ovarian cancer, breast cancer"
        ],
        "ambiguous": [
          "Definition of 'advanced' (e.g., metastatic, locally advanced, refractory) not specified",
          "Inclusion/exclusion of rare solid tumors unclear",
          "Age range not specified"
        ]
      },
      "intervention": {
        "explicit": [
          "Comprehensive genomic profiling (CGP)",
          "Next-generation sequencing (NGS)",
          "Genomic testing"
        ],
        "implicit": [
          "Use of CGP/NGS for biomarker identification",
          "Precision medicine approaches (targeted therapies, immunotherapies, tissue-agnostic therapies, multi-tumor type therapies, emerging molecularly targeted therapies)"
        ],
        "ambiguous": [
          "Specific platforms or panels for CGP/NGS not defined",
          "Extent of 'comprehensive' (whole exome, whole genome, large panels) not specified"
        ]
      },
      "comparator": {
        "explicit": [
          "Traditional genetic testing methods (PCR, chromosomal microarray, small gene panel assays)"
        ],
        "implicit": [
          "Standard of care without CGP/NGS",
          "No testing or limited biomarker testing"
        ],
        "ambiguous": [
          "Comparators for all outcomes not consistently specified (e.g., economic impact, clinical utility)",
          "Comparators for precision medicine approaches not always clear"
        ]
      },
      "outcome": {
        "explicit": [
          "Incidence and prevalence of advanced cancers",
          "List of EMA-approved and ESMO guideline-recommended biomarker-guided treatments",
          "Types of precision medicine approaches",
          "Unmet needs and challenges in genomic testing",
          "Clinical utility of CGP (coverage of biomarkers, accuracy, patient outcomes, biopsy requirements, clinical trial eligibility)",
          "Economic impact (budget impact, cost-effectiveness)"
        ],
        "implicit": [
          "Patient survival and response rates",
          "Number of patients eligible for targeted therapies or clinical trials",
          "Technical performance of genomic testing platforms"
        ],
        "ambiguous": [
          "Primary vs secondary outcomes not distinguished",
          "Patient-reported outcomes not mentioned",
          "Definition of 'clinical utility' may vary"
        ]
      },
      "study_design": {
        "explicit": [
          "Ongoing clinical trials (mentioned under emerging therapies)"
        ],
        "implicit": [
          "Epidemiological studies (for incidence/prevalence)",
          "Health economic evaluations",
          "Guideline and regulatory reviews",
          "Comparative effectiveness studies"
        ],
        "ambiguous": [
          "Inclusion/exclusion of observational studies, RCTs, real-world evidence not specified",
          "Systematic reviews/meta-analyses inclusion unclear"
        ]
      }
    },
    "gap_flags": [
      "Population definition",
      "Intervention specification",
      "Comparator clarity",
      "Outcome prioritization",
      "Study design inclusion",
      "Language restriction"
    ],
    "contraindications": [
      {
        "issue": "Broad scope across multiple cancer types, interventions, and outcomes",
        "severity": "high",
        "recommendation": "Consider narrowing focus or structuring review into sub-questions to improve feasibility and clarity"
      },
      {
        "issue": "Ambiguity in intervention and comparator definitions",
        "severity": "medium",
        "recommendation": "Clarify what constitutes CGP/NGS and traditional testing for consistent study selection"
      },
      {
        "issue": "Unclear inclusion/exclusion criteria for studies",
        "severity": "medium",
        "recommendation": "Define eligible study designs, populations, and settings"
      }
    ]
  }
}